Artikel ; Online: The evaluation of a multi-day testing approach with antigen lateral flow devices for people eligible for community-based COVID-19 treatments.
The Journal of antimicrobial chemotherapy
2023 Band 78, Heft Suppl 2, Seite(n) ii12–ii17
Abstract: Background: COVID-19 therapeutics including antiviral and monoclonal antibody treatments (hereafter 'COVID-19 treatments') require rapid administration to be effective. As part of the community-based antiviral and therapeutic treatment pathway for COVID- ...
| Abstract | Background: COVID-19 therapeutics including antiviral and monoclonal antibody treatments (hereafter 'COVID-19 treatments') require rapid administration to be effective. As part of the community-based antiviral and therapeutic treatment pathway for COVID-19 there has been a move from PCR testing in those eligible to a rapid antigen lateral flow testing regime. Objectives: To determine whether a multi-day lateral flow device (LFD) testing regime is a feasible alternative to PCR for diagnosing symptomatic patients eligible for COVID-19 treatments. An LFD regime might return a positive result more quickly than a PCR and hence expedite access to COVID-19 treatments. Methods: A retrospective analysis was conducted of diagnostic testing for SARS-CoV-2 with a combination of PCR and LFDs of symptomatic patients eligible for COVID-19 treatments. LFD testing patterns were not assigned. Patients self-censored and the patterns were retro-fitted to the observed results. Results: The LFD testing patterns offered high sensitivity, close to 92%; however, the false positive rate also increased, with most of the multi-day testing patterns having a false positive rate greater than 3%. The highest sensitivity was seen among patients who tested with LFD on the same day as PCR. Conclusions: There were multiple observed testing behaviours. We conclude that multi-day LFD testing for COVID-19 provides a feasible alternative to PCR to in eligible patients, allowing swift prescription of COVID-19 treatments in most cases. This approach requires acceptance of a trade-off for a small increase in false-positive and -negative results. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mesh-Begriff(e) | Humans ; COVID-19/diagnosis ; SARS-CoV-2 ; COVID-19 Drug Treatment ; COVID-19 Testing ; Retrospective Studies ; Antiviral Agents/therapeutic use ; Sensitivity and Specificity | ||||||||||
| Chemische Substanzen | Antiviral Agents | ||||||||||
| Sprache | Englisch | ||||||||||
| Erscheinungsdatum | 2023-11-23 | ||||||||||
| Erscheinungsland | England | ||||||||||
| Dokumenttyp | Journal Article ; Research Support, Non-U.S. Gov't | ||||||||||
| ZDB-ID | 191709-2 | ||||||||||
| ISSN | 1460-2091 ; 0305-7453 | ||||||||||
| ISSN (online) | 1460-2091 | ||||||||||
| ISSN | 0305-7453 | ||||||||||
| DOI | 10.1093/jac/dkad313 | ||||||||||
| Signatur |
|
||||||||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 1197: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 124: Hefte anzeigen |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.